Chan Mitchell 4

What Happened Chan Mitchell, a director of Avalo Therapeutics (AVTX), sold 3,167 shares in an open-market transaction on May 6, 2026. The shares were sold at $22.88 per share for total proceeds of approximately $72,461. This was a sale (not a purchase) and sales by insiders are often routine liquidity events rather than clear signals about company outlook.

Key Details

• Transaction date: May 6, 2026; Price: $22.88 per share; Total proceeds: ~$72,461.
• Transaction type: Sale (reported as "open market or private sale" on the Form 4).
• Shares owned after the transaction: Not disclosed in the provided filing.
• Footnote: The sale was executed under a pre-established Rule 10b5-1 trading plan adopted by Mitchell on November 19, 2025.
• Filing date: Form 4 filed May 7, 2026 — appears to be timely (filed within the standard 2-business-day window).

Context Trades done under 10b5-1 plans are prearranged and can help insiders sell shares without being influenced by current nonpublic information; they are common for scheduled disposals. For retail investors, purchases typically carry more informational weight than routine insider sales, but tracking patterns of insider activity over time can be informative.